Search - tctmd.com

Displaying 1 - 20 of 25

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

News Conference News TCT 2023

BIOSTEMI: Degradable-Polymer, Ultrathin-Strut DES Shows No Late Catch-up at 5 Years

October 27, 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

News Conference News SCAI 2023

SPIRIT 48: Long DES for Diffuse CAD Highly Deliverable, Safe at 1 Year

May 31, 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

News Conference News ACC 2023

Short DAPT Noninferior to 1 Year After Ultrathin DES PCI: HOST-IDEA

Yael L. Maxwell

March 09, 2023

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

News Conference News CRT 2023

‘Beeting’ In-stent Restenosis? Dietary Nitrate May Improve Outcomes

Yael L. Maxwell

February 27, 2023

SCAAR Registry Delves Into Left Main Revascularization Outcomes

News Conference News TCT 2022

SCAAR Registry Delves Into Left Main Revascularization Outcomes

Michael O'Riordan

September 19, 2022

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

March 02, 2022

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

October 25, 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

News Conference News EuroPCR 2021

Ultrathin Orsiro Performs Well in All-Comers, Interim CASTLE Data Indicate

May 24, 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

News Conference News EuroPCR 2021

The Skinny on Ultrathin DES: Meta-analysis Shows Some Long-term Advantages

May 19, 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

News Conference News CRT 2021

BIOSTEMI at 2 Years: Orsiro Continues to Lower TLF in STEMI Patients

March 16, 2021

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

November 19, 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

October 22, 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

October 17, 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

October 17, 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

News Conference News TCT 2020

Shorter DAPT Succeeds in Xience-Treated Patients at High Bleeding Risk

October 15, 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

News Conference News CRT 2020

Newer, Thinner-Strut Abbott Scaffold Prompts Talk of a BVS Comeback

Michael O'Riordan

February 28, 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

News Conference News CRT 2020

BIOFLOW V: Orsiro Bests Xience at 3 Years for TLF, Late Stent Thrombosis

February 25, 2020

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

News Conference News TCT 2019

IVUS-XPL at 5 Years Shows Durability of Imaging Guidance in PCI

October 08, 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

News Conference News TCT 2019

PICCOLETO II: More Support for DCB Safety and Efficacy in Small Coronaries

October 04, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.